success
therapeut
synerg
aprotinin
rimantadin
known
attack
differ
viral
target
demonstr
influenzavirusinfect
anim
combin
treatment
drug
mice
infect
highli
lethal
dose
mouseadapt
influenza
viru
prevent
develop
fatal
haemorrhag
pneumonia
protect
anim
wherea
separ
administr
aprotinin
rimantadin
induc
protect
respect
rimantadin
known
induc
protect
influenzavirusinfect
mice
grunert
et
al
antivir
drug
found
block
intern
viru
host
cell
skehel
et
al
koff
knight
bukrinskaya
et
al
seem
damag
assembl
virion
infect
cell
hay
et
al
report
also
protect
mice
lethal
infect
influenza
viru
could
perform
aprotinin
zhirnov
et
al
polypeptid
antiproteinas
trautschold
et
al
compound
demonstr
inhibit
proteolyt
cleavag
viru
haemagglutinin
zhirnov
et
al
thu
prevent
activ
progeni
virion
reduc
spread
infect
zhirnov
et
al
unlik
rimantadin
grunert
et
al
aprotinin
observ
induc
mark
protect
anim
infect
influenza
viru
administ
earli
also
follow
administr
later
infect
zhirnov
et
al
shown
drug
affect
differ
stage
viru
replic
abl
induc
synergist
therapeut
effect
anim
infect
influenza
viru
studi
n
methyladamantan
hydrochlorid
rimantadin
obtain
institut
organ
synthesi
latvian
academi
scienc
u
r
aprotinin
commerci
solut
gordox
produc
gedeon
richter
hungari
use
aprotinin
disulfidelink
polypeptid
dimer
molecular
weight
inhibit
wide
spectrum
proteinas
trypsin
chymotrypsin
cathepsin
plasmin
etc
trautschold
et
al
obtain
anim
organ
wide
use
medic
practic
prevent
hyperfibrinolysi
treat
pancreat
amri
trapnel
et
al
muller
et
al
respect
antiproteinas
specif
compound
analog
trasylol
produc
bayer
ag
mali
et
al
possibl
suppress
influenza
paramyxoviru
infect
chicken
embryo
mice
gordox
zhirnov
et
al
mouseadapt
influenza
viru
aaichi
propag
allanto
sac
embryon
chicken
egg
passag
low
multipl
titr
viru
allanto
fluid
usual
x
pfuml
haemagglutin
unitsml
viru
infect
titrat
chicken
fibroblast
standard
plaqu
assay
trypsin
agar
overlay
zhirnov
et
al
mice
g
infect
intranas
plmous
light
ether
narcosi
mouseadapt
viru
aaichi
multipl
mous
lethal
dose
x
pfu
per
mous
infect
either
physiolog
salin
placebo
gordox
kallikrein
inhibit
unitdmous
rimantadin
pgmous
dose
drug
inject
intraperiton
ml
physiolog
salin
interv
day
group
usual
contain
anim
dose
compound
examin
induc
visibl
toxic
death
anim
condit
administr
protect
effect
antiinfluenz
drug
examin
studi
mice
infect
influenza
aaichi
viru
viru
strain
adapt
mous
lung
mousetomous
intranas
passag
adapt
replic
effect
mous
lung
induc
fatal
haemorrhag
pneumonia
zhirnov
et
al
experi
design
studi
combin
aprotininrimantadin
therapi
carri
mice
infect
highli
lethal
dose
viru
chosen
order
estim
therapeut
synerg
aprotinin
rimantadin
sinc
separ
administr
condit
found
protect
less
anim
see
infect
aprotinin
rimantadin
inject
intraperiton
interv
day
singl
inject
dose
aprotinin
rimantadin
kiu
pg
per
mous
respect
dose
chosen
accord
previou
data
indic
mark
antivir
activ
aprotinin
zhirnov
et
al
rimantadin
grunert
et
al
galegov
et
al
influenzainfect
mice
result
typic
experi
show
surviv
mice
treat
aprotinin
rimantadin
repres
figur
seen
group
placebotr
anim
lethal
regist
day
infect
protect
due
rimantadin
aprotinin
treatment
respect
moreov
death
mice
delay
aprotinin
rimantadin
day
respect
see
fig
combin
chemotherapi
drug
protect
anim
death
occur
day
later
rimantadineaprotinintr
anim
placebotr
one
success
therapeut
effect
aprotininrimantadin
combin
influenzainfect
mice
also
demonstr
examin
pulmonari
patholog
seen
figur
fatal
confluent
haemorrhag
inflamm
lung
tissu
placebotr
mice
loci
haemorrhag
mild
haemorrhag
inflamm
lung
aprotinin
rimantadinetr
mice
mice
treat
drug
lung
patholog
minim
sole
loci
nonhaemorrhag
pneumonia
regist
see
fig
data
report
show
aprotinin
rimantadin
produc
synergist
protect
mice
lethal
infect
influenza
viru
therapeut
synerg
reveal
probabl
result
differ
antivir
target
compound
previous
propos
pathway
influenza
virus
undergo
proteolyt
activ
develop
via
viciou
circl
zhirnov
idea
illustr
figur
follow
activ
host
proteinas
goldberg
lazarowitz
lazarowitz
et
al
degtyarenko
et
al
action
proteinas
probabl
one
trigger
factor
inflammatori
reaction
fibrinolyticclot
system
defect
often
observ
influenza
davison
et
al
lindsay
et
al
nobl
et
al
louria
et
al
hand
host
proteinas
cleav
viru
haemagglutinin
glycopolypeptid
ha
molecular
weight
kd
two
disulfidelink
fragment
kd
kd
activ
virion
infect
klenk
et
al
lazarowitz
choppin
realiz
viru
virul
host
organ
bosch
et
al
rott
et
al
valloracht
et
al
summaris
higher
induct
viru
strain
host
proteinas
activ
lead
intens
viru
proteolyt
activ
viru
spread
develop
host
organ
review
see
zhirnov
follow
supposit
proteinas
inhibitor
includ
aprotinin
may
normal
proteolyt
balanc
limit
inflammatori
process
develop
syndrom
andersen
appleyard
tisdal
hand
antiproteinas
tpck
tlck
pmsf
aprotinin
fail
block
penetr
measl
viru
coronaviru
host
cell
appleyard
tisdal
richardson
choppin
haemorrag
coagul
defect
may
suppress
proteolyt
activ
virion
reduc
viru
multicycl
replic
spread
see
fig
also
follow
rimantadin
attack
target
viru
replic
prevent
penetr
infecti
virion
host
cell
disturb
assembl
virion
target
differ
stage
influenza
viru
pathogen
pathway
thought
main
mechan
synergist
antiinfluenz
therapeut
action
combin
aprotininrimantadin
treatment
aprotinin
rimantadin
medicin
compound
synergist
antiinfluenz
effect
report
suggest
combin
aprotininrimantadin
antiinfluenza
therapi
might
use
clinic
trail
man
influenza
viru
infect
primarili
local
upper
respiratori
tract
therefor
seem
expedi
use
aerosol
inhal
compound
first
clinic
observ
outbreak
influenza
demonstr
antivir
therapeut
efficasi
aerosol
inhal
antiproteinas
zhirnov
et
al
rimantadin
hayden
et
al
base
find
seem
feasibl
design
manual
inhal
antiproteinas
agent
rimantadin
inhal
thought
make
earlier
prophylact
therapeut
applic
compound
possibl
especi
influenza
outbreak
epidem
pleasur
thank
professor
nv
kaverin
help
discuss
would
also
like
acknowledg
invalu
help
advic
dr
av
ovcharenko
assist
manuscript
ms
svetlana
kassianova
grate
acknowledg
